Insilico's AI-designed drug appears to slow biological aging

Insilico Medicine reported that its AI-designed drug rentosertib reduced participants' predicted biological age by about three years on average in a Phase IIa trial, improving six biological aging clocks and raising hopes of halting biological aging.

2026-09-09 ~ 2026-09-10 · 2 related posts

• Insilico's AI-designed fibrosis drug cuts predicted biological age by ~3 years — Polymarket · 2026-09-09
• AI-Designed Drug Rentosertib Shifts Six Aging Clocks in Phase IIa Trial — AIFlow_ML · 2026-09-10